Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Galderma’s Ph III Nemolizumab Trials Show Positive Results in Atopic Dermatitis

Jul 25, 2024

On 25 July 2024, Galderma announced that results from its Phase III trials on nemolizumab, published in The Lancet, demonstrate statistically and clinically significant improvements in inflammation and itch in moderate to severe atopic dermatitis.  The studies evaluated the efficacy and safety of nemolizumab in combination with background topical corticosteroids (TCS), with or without topical calcineurin inhibitors (TCI), versus placebo in combination with TCS, with or without TCI.

On 7 May 2024, Galderma announced that nemolizumab had been accepted for review, under the Access Consortium Framework, in Australia, Singapore, Switzerland and the UK for prurigo nodularis and moderate to severe atopic dermatitis.  Regulatory filings for nemolizumab were accepted by the FDA and EMA in February 2024.